يعرض 1 - 5 نتائج من 5 نتيجة بحث عن '"Comas Navarro, Raquel"', وقت الاستعلام: 0.97s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Ros J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Matito J, Comas R, Garcia A, Toledo R, Dientsmann R, Vivancos A Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Villacampa G Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. The Institute of Cancer Research, London, UK. Martini G Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Baraibar I, Saoudi N, Salvà F, Tabernero J, Elez E Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martin Á Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Annals of Oncology;34(6); https://doi.org/10.1016/j.annonc.2023.02.016Test; info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00968; Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023 Jun;34(6):543–52.; https://hdl.handle.net/11351/9929Test

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Baraibar I, Salvà F, Ros J, Saoudi N, García-Álvarez A, Hernando J, Capdevila J, Castells MR, Tabernero J, Élez E Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. García A, Comas R, Castillo G, Sanchis M Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martí M, Espín E, Dopazo C Servei de Cirurgia General i Digestiva, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Landolfi S Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Navalpotro B Servei d’Oncologia Radioteràpica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Guevara J Servei d’Aparell Digestiu, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Nuciforo P, Vivancos A Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Translational Oncology;32; https://doi.org/10.1016/j.tranon.2023.101668Test; Baraibar I, García A, Salvà F, Ros J, Saoudi N, Comas R, et al. Impact of the COVID-19 pandemic in the early-onset colorectal cancer. Transl Oncol. 2023 Jun;32:101668.; https://hdl.handle.net/11351/9430Test; 000866211600326

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Élez E, Argilés G, Sanz-Garcia E, Baraibar I, Salvà F, Noguerido A, Garcia A, Tabernero J Colorectal Cancer Program, Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Mulet-Margalef N Colorectal Cancer Program, Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Colorectal Cancer Unit, Medical Oncology Department, Catalan Institute of Oncology, L’Hospitalet de Llobregat, Barcelona, Spain. Sanso M Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Genomics for Precision Oncology Laboratory, Fundació Institut d’Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, Spain. Ruiz-Pace F, Comas R, Dienstmann R Oncology Data Science Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Mancuso FM Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Research and Development Department, Universal Diagnostics S.L., Sevilla, Spain. Ros J, Martini G Colorectal Cancer Program, Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Cuadra-Urteaga JL Colorectal Cancer Program, Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medical Oncology, IOB—Hospital Quirón, Barcelona, Spain. Fasani R, Jimenez J, Nuciforo P Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Aguilar S Molecular Prescreening Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Landolfi S, Hernández-Losa J Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Braña I Medical Oncology Department, Research Unit for Molecular Therapy of Cancer, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Salazar R Colorectal Cancer Unit, Medical Oncology Department, Catalan Institute of Oncology, L’Hospitalet de Llobregat, Barcelona, Spain. Medical Oncology Department, Research Unit for Molecular Therapy of Cancer, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vivancos A Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: International Journal of Molecular Sciences;24(1); https://doi.org/10.3390/ijms24010118Test; Élez E, Mulet-Margalef N, Sanso M, Ruiz-Pace F, Mancuso FM, Comas R, et al. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. Int J Mol Sci. 2022 Dec 21;24(1):118.; https://hdl.handle.net/11351/9154Test; 000909932600001

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Elez E Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Ros J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Fernández J, Villacampa G, Moreno-Cárdenas AB, Bernatowicz K, Comas R, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Vivancos A, Dienstmann R Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Arenillas C, Toledo RA Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain. Perez-Lopez R Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Tabernero J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain. UVic-UCC, IOB-Quirón, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Nature Medicine;28; https://doi.org/10.1038/s41591-022-01976-zTest; info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F12%2F00259; info:eu-repo/grantAgreement/ES/PERIS2016-2020/SLT008%2F18%2F00198; info:eu-repo/grantAgreement/ES/PERIS2016-2020/SLT008%2F18%2F00205; info:eu-repo/grantAgreement/ES/PE2017-2020/CEX2020-001024-S; info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01395; info:eu-repo/grantAgreement/ES/PE2017-2020/PI21%2F01019; info:eu-repo/grantAgreement/ES/PE2013-2016/CP17%2F00199; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00947; info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00968; info:eu-repo/grantAgreement/ES/PE2017-2020/ECT2020-000827; Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, et al. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat Med. 2022 Oct;28:2162–70.; https://hdl.handle.net/11351/8672Test; 000852940800004

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Serna G, Alonso L, Fasani R, Jimenez J, Nuciforo P Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Ruiz-Pace F, Comas R, Dienstmann R Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Hernando J, Elez E, Capdevila J Servei d’Oncologia Mèdica, Unitat de Tumors gastrointestinals i endocrins, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. Landolfi S Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Tabernero J Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf; image/jpeg

    العلاقة: Annals of Oncology;31(10); https://doi.org/10.1016/j.annonc.2020.06.003Test; Serna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020 Oct;31(10):1366–75.; https://hdl.handle.net/11351/6378Test; 000574680100001